The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis

We evaluated the incidence of and the main risk factors associated with cutaneous adverse events in patients with chronic inflammatory arthritis following anti-TNF-α therapy. A total of 257 patients with active arthritis who were taking TNF-α blockers, including 158 patients with rheumatoid arthriti...

Full description

Saved in:
Bibliographic Details
Published in:Clinics (São Paulo, Brazil) Brazil), 2013-09, Vol.68 (9), p.1189-1196
Main Authors: Machado, Natalia P., dos Reis Neto, Edgard Torres, Soares, Maria Roberta M.P., Freitas, Daniele S., Porro, Adriana, Ciconelli, Rozana M., Pinheiro, Marcelo M.
Format: Article
Language:English
Subjects:
Adult
Adverse Events
Age Factors
Ankylosing Spondylitis
Antibodies, Monoclonal - adverse effects
Antirheumatic Agents - adverse effects
Arthritis - drug therapy
Arthritis, Psoriatic - drug therapy
Chronic Disease
Clinical Science
Female
Follow-Up Studies
Humans
Male
MEDICINE, GENERAL & INTERNAL
Middle Aged
Prospective Studies
Rheumatoid Arthritis
Risk Factors
Severity of Illness Index
Sex Factors
Skin
Skin - drug effects
Skin Diseases - chemically induced
Spondylitis, Ankylosing - drug therapy
Statistics, Nonparametric
Surveys and Questionnaires
Time Factors
TNF-alpha Blockers
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the incidence of and the main risk factors associated with cutaneous adverse events in patients with chronic inflammatory arthritis following anti-TNF-α therapy. A total of 257 patients with active arthritis who were taking TNF-α blockers, including 158 patients with rheumatoid arthritis, 87 with ankylosing spondylitis and 12 with psoriatic arthritis, were enrolled in a 5-year prospective analysis. Patients with overlapping or other rheumatic diseases were excluded. Anthropometric, socioeconomic, demographic and clinical data were evaluated, including the Disease Activity Score-28, Bath Ankylosing Spondylitis Disease Activity Index and Psoriasis Area Severity Index. Skin conditions were evaluated by two dermatology experts, and in doubtful cases, skin lesion biopsies were performed. Associations between adverse cutaneous events and clinical, demographic and epidemiological variables were determined using the chi-square test, and logistic regression analyses were performed to identify risk factors. The significance level was set at p
ISSN:1807-5932
1980-5322
1980-5322
DOI:10.6061/clinics/2013(09)03